Advanced search
Publication Cover
Future Virology Volume 7, 2012 - Issue 9
Submit an article Journal homepage
30
Views
0
CrossRef citations to date
0
Altmetric
Review

Viral, Host and Therapeutic Factors Affecting T-cell Recovery in Virologically Controlled HIV Patients

Carmela Pinnetti1 Division of Infectious Diseases, Department of Internal Medicine, ‘San Gerardo‘ Hospital, University of Milan-Bicocca, Via Pergolesi 33, 20052 Monza, Milan, Italy
,
Alessandra Bandera1 Division of Infectious Diseases, Department of Internal Medicine, ‘San Gerardo‘ Hospital, University of Milan-Bicocca, Via Pergolesi 33, 20052 Monza, Milan, Italy
,
Davide Mangioni1 Division of Infectious Diseases, Department of Internal Medicine, ‘San Gerardo‘ Hospital, University of Milan-Bicocca, Via Pergolesi 33, 20052 Monza, Milan, Italy
&
Andrea Gori1 Division of Infectious Diseases, Department of Internal Medicine, ‘San Gerardo‘ Hospital, University of Milan-Bicocca, Via Pergolesi 33, 20052 Monza, Milan, ItalyCorrespondence[email protected]
Pages 911-921 | Published online: 21 Sep 2012

References

  • Moorman AC , HolmbergSD, MarloweSI et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). Ann. Epidemiol. 9(6) , 349–357 (1999).
  • Street E , CurtisH, SabinCA, MonteiroEF, JohnsonMA. British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naive. HIV Med.10(6) , 337–342 (2009).
  • Tan R , WestfallAO, WilligJH et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr.47(5) , 553–558 (2008).
  • Robbins GK , SpritzlerJG, ChanES et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin. Infect. Dis. 48(3) , 350–361 (2009).
  • Carcelain G , BlancC, LeibowitchJ et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS13(9) , 1077–1081 (1999).
  • Gazzola L , TincatiC, BellistrìGM, MonforteA, MarchettiG. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin. Infect. Dis.48(3) , 328–337 (2009).
  • Zoufaly A , an der Heiden M, Kollan C et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J. Infect. Dis.203(3) , 364–371 (2011).
  • Losa GA , GraberR. Spontaneous apoptosis, oxidative status and immunophenotype markers in blood lymphocytes of AIDS patients. Anal. Cell Pathol.21(1) , 11–20 (2000).
  • Burgoyne RW , TanDH. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J. Antimicrob. Chemother.61(3) , 469–473 (2008).
  • Van Lelyveld SF , WindCM, MudrikovaT, van Leeuwen HJ, de Lange DW, Hoepelman AI. Short- and long-term outcome of HIV-infected patients admitted to the intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis.30(9) , 1085–1093 (2009).
  • Gutiérrez F , BernalE, PadillaS, HernándezI, MasiáM. Relationship between ankle-brachial index and carotid intima-media thickness in HIV-infected patients. AIDS22(11) , 1369–1371 (2008).
  • Chávez-Galán L , Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R. Cell death mechanisms induced by cytotoxic lymphocytes. Cell. Mol. Immunol.6(1) , 15–25 (2009).
  • Benveniste O , FlahaultA, RollotF et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J. Infect. Dis. 191(10) , 1670–1679 (2005).
  • Février M , DorghamK, RebolloA. CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses3(5) , 586–612 (2011).
  • Thiele J , ZirbesTK, BertschHP, TitiusBR, LorenzenJ, FischerR. AIDS-related bone marrow lesions – myelodysplastic features or predominant inflammatory-reactive changes (HIV-myelopathy)? A comparative morphometric study by immunohistochemistry with special emphasis on apoptosis and PCNA-labeling. Anal. Cell. Pathol.11(3) , 141–157 (1996).
  • Feinberg MB , MooreJP. AIDS vaccine models: challenging challenge viruses. Nat. Med.8(3) , 207–210 (2002).
  • Lederman MM , CalabreseL, FunderburgNT et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J. Infect. Dis. 204(8) , 1217–1226 (2011).
  • Autran B , CarcelainG, LiTS et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277(5322) , 112–116 (1997).
  • Guihot A , BourgaritA, CarcelainG, AutranB. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol.32(3) , 131–137 (2011).
  • Rehr M , CahenzliJ, HaasA et al. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J. Virol. 82 , 3391–3404 (2008).
  • Benito JM , LopezM, MartinJC et al. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors. AIDS Res. Hum. Retroviruses 18 , 1379–1388 (2002).
  • Hunt PW , BrenchleyJ, SinclairE et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV-RNA levels in the absence of therapy. J. Infect. Dis. 197 , 126–133 (2008).
  • Massanella M , NegredoE, Perez-AlvarezN et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 24(7) , 959–968 (2010).
  • Nakanjako D , SsewanyanaI, Mayanja-KizzaH et al. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect. Dis. 192 , 2142–2146 (2005).
  • Hunt PW , CarringtonM. Host genetic determinants of HIV pathogenesis: an immunologic perspective. Curr. Opin. HIV AIDS3(3) , 342–348 (2008).
  • Gras L , KesselringAM, GriffinJT et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J. Acquir. Immune Defic. Syndr. 45(2) , 183–192 (2007).
  • Guihot A , TubianaR, BretonG et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 24(4) , 614–617 (2010).
  • Diaz A , AlosL, LeonA et al. Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients. AIDS 24 , 2029–2039 (2010).
  • Brenchley JM , SchackerTW, RuffLE et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200(6) , 749–759 (2004).
  • Engsig FN , GerstoftJ, KronborgG et al. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect. Dis. 10 , 318 (2010).
  • Rickabaugh TM , JamiesonBD. A challenge for the future: aging and HIV infection. Immunol. Res.48(1–3) , 59–71 (2010).
  • Appay V , Rowland-JonesSL. Premature ageing of the immune system: the cause of AIDS? Trend. Immun.23(12) , 580–585 (2002).
  • Deeks SG , PhillipsAN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ338 , a3172 (2009).
  • Rickabaugh TM , KilpatrickRD, HultinLE et al. The dual impact of HIV-1 infection and aging on naive CD4 T-cells: additive and distinct patterns of impairment. PLoS One 6(1) , e16459 (2011).
  • Miller MF , HaleyC, KozielMJ, RowleyCF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin. Infect. Dis.41(5) , 713–720 (2005).
  • Peters L , MocroftA, SorianoV et al. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J. Acquir. Immune Defic. Syndr. 50(5) , 457–463 (2009).
  • Hernandez MD , ShermanKE. HIV/hepatitis C coinfection natural history and disease progression. Curr. Opin. HIV AIDS6(6) , 478–482 (2011).
  • Potter M , OdueyungboA, YangH, SaeedS, KleinMB. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS24(12) , 1857–1865 (2010).
  • Körner C , TolksdorfF, RiesnerK et al. Hepatitis C coinfection enhances sensitization of CD4(+) T-cells towards Fas-induced apoptosis in viraemic and HAART-controlled HIV-1-positive patients. Antivir. Ther. 16(7) , 1047–1055 (2011).
  • Milazzo L , FoschiA, MazzaliC et al. Impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. AIDS Res. Hum. Retroviruses doi:10.1089/aid.0323 (2012) (Epub ahead of print) (2011).
  • Reiberger T , PayerBA, KosiL, HeilPM, RiegerA, Peck-RadosavljevicM. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients. J. Infect. Dis.15 , 1802–1806 (2011).
  • Appay V , FastenackelsS, KatlamaC et al. Old age and anti-CMV immunity are associated with altered T cell reconstitution in HIV-1 infected patients. AIDS 25 , 1813–1822 (2011).
  • Doyle T , GerettiAM. Low-level viraemia on HAART: significance and management. Curr. Opin. Infect. Dis.25(1) , 17–25 (2012).
  • Nicastri E , PalmisanoL, SarmatiL et al. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens. Curr. HIV Res. 6(3) , 261–266 (2008).
  • Palmer S , MaldarelliF, WiegandA et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA 11 , 3879–3884 (2008).
  • Chun TW , MurrayD, JustementJS et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J. Infect. Dis. 204(1) , 135–138 (2011).
  • Marchetti G , GoriA, CasabiancaA et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 20(13) , 1727–1736 (2006).
  • Delobel P , Sandres-SaunéK, CazabatM et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 38(4) , 382–392 (2005).
  • Delobel P , NugeyreMT, CazabatM et al. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J. Virol. 80(20) , 10229–10236 (2006).
  • Mavigner M , DelobelP, CazabatM et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 4(10) , e7658 (2009).
  • Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med.338(13) , 853–860 (1998).
  • Lohse N , HansenAB, GerstoftJ, ObelN. Improved survival in HIV-infected persons: consequences and perspectives. J. Antimicrob. Chemother.60(3) , 461–463 (2007).
  • Lewden C , CheneG, MorlatP et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. 46(1) , 72–77 (2007).
  • Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V et al. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int. J. Epidemiol.41(2) , 433–445 (2012).
  • Bhaskaran K , HamoudaO, SannesM et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300(1) , 51–59 (2008).
  • Lewden C , MayT, RosenthalE et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic). J. Acquir. Immune Defic. Syndr. 48(5) , 590–598 (2008).
  • Hunt PW , MartinJN, SinclairE et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187(10) , 1534–1543 (2003).
  • Gandhi RT , SpritzlerJ, ChanE et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J. Acquir. Immune Defic. Syndr. 42(4) , 426–434 (2006).
  • Valdez H , ConnickE, SmithKY et al. Limited immune restoration after 3 years‘ suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 16(14) , 1859–1866 (2002).
  • Goicoechea M , SmithDM, LiuL et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J. Infect. Dis. 194(1) , 29–37 (2006).
  • French MA , KingMS, TschampaJM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J. Infect. Dis.200(8) , 1212–1215 (2009).
  • Hatano H , DelwartEL, NorrisPJ et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24(16) , 2535–2539 (2010).
  • Neuhaus J , JacobsDR Jr, Baker JV et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis.201(12) , 1788–1795 (2010).
  • Eastburn A , ScherzerR, ZolopaAR et al. Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One 6(11) , e26320 (2011).
  • Guadalupe M , ReayE, SankaranS et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77(21) , 11708–11717 (2003).
  • Mehandru S , PolesMA, Tenner-RaczK et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200(6) , 761–770 (2004).
  • Veazey RS , LacknerAA. The gastrointestinal tract and the pathogenesis of AIDS. AIDS12(Suppl. A) , S35–S42 (1998).
  • Brenchley JM , PriceDA, SchackerTW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12(12) , 1365–1371(2006).
  • Li Q , EstesJD, DuanL et al. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J. Infect. Dis. 197(3) , 420–429 (2008).
  • Sodora DL , SilvestriG. Immune activation and AIDS pathogenesis. AIDS22(4) , 439–446 (2008).
  • Hunt PW . Th17, gut, and HIV: therapeutic implications. Curr. Opin. HIV AIDS5(2) , 189–193 (2010).
  • Iwakura Y , IshigameH, SaijoS, NakaeS. Functional specialization of interleukin-17 family members. Immunity34(2) , 149–162 (2011).
  • Liang SC , TanXY, LuxenbergDP et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203(10) , 2271–2279 (2006).
  • Prendergast A , PradoJG, KangYH et al. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS24(4) , 491–502 (2010).
  • Brenchley JM , PaiardiniM, KnoxKS et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112(7) , 2826–2835 (2008).
  • Favre D , LedererS, KanwarB et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 5(2) , e1000295 (2009).
  • Raffatellu M , SantosRL, VerhoevenDE et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat. Med. 14(4) , 421–428 (2008).
  • Gori A , TincatiC, RizzardiniG et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J. Clin. Microbiol. 46(2) , 757–758 (2008).
  • Jiang W , LedermanMM, HuntP et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199(8) , 1177–1185 (2009).
  • Marchetti G , BellistrìGM, BorghiE et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 22(15) , 2035–2038 (2008).
  • Rajasuriar R , BoothD, SolomonA et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J. Infect. Dis. 202(8) , 1254–1264 (2010).
  • Koch S , SolanaR, Dela Rosa O, Pawelec G. Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech. Ageing Dev.127(6) , 538–543 (2006).
  • Sauce D , LarsenM, FastenackelsS et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 117(19) , 5142–5151 (2011).
  • Moses A , NelsonJ, BagbyGC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood91(5) , 1479–1495 (1998).
  • Isgrò A , LetiW, De Santis W et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin. Infect. Dis.46(12) , 1902–1910 (2008).
  • Franco JM , RubioA, Martínez-MoyaM et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 99(10) , 3702–3706 (2002).
  • Li T , WuN, DaiY et al. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin. Infect. Dis. 53(9) , 944–951 (2011).
  • Molina-Pinelo S , VallejoA, DíazL et al. Premature immunosenescence in HIV-infected patients treated on highly active antiretroviral therapy with low-level CD4+ T cell repopulation. JAC 64 , 579–588 (2009).
  • Bandera A , FerrarioG, SaresellaM et al. CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals. PLoS One 5(5) , e10788 (2010).
  • Napolitano LA , GrantRM, DeeksSG et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 7(1) , 73–79 (2001).
  • Marziali M , De Santis W, Carello R et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS20(16) , 2033–2041 (2006).
  • Fellay J . Host genome influences on HIV-1 disease. Antivir. Ther.14 , 731–738 (2009).
  • Ahuja SK , KulkarniH, CatanoG et al.CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med.14 , 413–420 (2008).
  • Fernandez S , RosenowAA, JamesIR et al. Reovery of CD4+ T cells in HIV patients with a stable virologic response to antiretroviral therapy is associated with polymorphisms of interelukin-6 and central major histocompatibility complex genes. J. Acquir. Immune Defic. Syndr. 41 , 1–5 (2006).
  • Haas DW , GeraghtyDE, AndersenJ et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trial Group study. J. Infect. Dis. 194 , 1098–1107 (2006).
  • Fellay J , ShiannaKV, GeD et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317(5840) , 944–947 (2007).
  • Kosmrlj A , ReadEL, QiY et al. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465(7296) , 350–354 (2010).
  • Lanier LL . NK cell recognition. Annu. Rev. Immunol.23 , 225–274 (2005).
  • Martin MP , GaoX, LeeJH et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31(4) , 429–434 (2002).
  • Alter G , MartinMP, TeigenN et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204(12) , 3027–3036 (2007).
  • Soria A , GueriniFR, BanderaA et al. KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy. PLoS One 6(11) , e27349 (2011).
  • Buzón MJ , MassanellaM, LlibreJM et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16(4) , 460–465 (2010).
  • Yukl SA , ShergillAK, McQuaidK et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 24(16) , 2451–2460 (2010).
  • Gandhi RT , CoombsRW, ChanES et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 59(3) , 229–235 (2012).
  • Hatano H , HayesTL, DahlV et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J. Infect. Dis. 203(7) , 960–968 (2011).
  • Gutiérrez C , DíazL, VallejoA et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One 6(12) , e27864 (2011).
  • Rusconi S . Investigators involvement in the care of HIV-infected individuals: the experience in recent clinical trials. J. Acquir. Immune Defic. Syndr.58(4) , 118–119 (2011).
  • Gori A , RizzardiniG, Van‘t Land B et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial. Mucosal Immunol.4(5) , 554–563 (2011).
  • Byakwaga H , KellyM, PurcellDF et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J. Infect. Dis. 204(10) , 1532–1540 (2011).
  • Piconi S , ParisottoS, RizzardiniG et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 118(12) , 3263–3272 (2011).
  • Hunt PW , MartinJN, SinclairE et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J. Infect. Dis. 203(10) , 1474–1483 (2011).
  • Marchetti G , MeroniL, MolteniC et al. IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients. Antivir. Ther. 9(3) , 447–452 (2004).
  • Sabbatini F , BanderaA, FerrarioG et al. Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients. PLoS One 5(11) , e14119 (2010).
  • INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med.361(16) , 1548–1559 (2009).
  • Levy Y , LacabaratzC, WeissL et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 119(4) , 997–1007 (2009).
  • Sereti I , DunhamRM, SpritzlerJ et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113(25) , 6304–6314 (2009).
  • Camargo JF , KulkarniH, AganBK et al. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression. J. Infect. Dis. 199(12) , 1872–1882 (2009).
  • Imamichi H , DegrayG, AsmuthDM et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 25(2) , 159–164 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.